NLRP1 and Alzheimer disease: To eliminate the influence of the JAK/STAT signaling pathway involved in the TTP488-mediated recovery of AD injury, which occurred via NLRP1 inflammasome activation, we used tofacitinib and fludarabine, which are specific inhibitors of JAK and STAT, respectively (Figure 5).